HCT-话题@MedSci - 梅斯（MedSci）

#HCT#

19篇内容 | 1430人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2191802, encodeId=b6f521918023b, content=<a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a> <a href='/topic/show?id=bd8495014c0' target=_blank style='color:#2F92EE;'>#造血细胞移植#</a>, objectTitle=BMT：欧洲2022年移植和细胞治疗的规模：CAR-T稳步增长，移植增长放缓, objectType=article, longId=816090, objectId=e8e3816090aa, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894905510_4754896.jpeg, objectUrl=/article/show_article.do?id=e8e3816090aa, replyNumber=0, likeNumber=91, createdTime=2024-03-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e8e3816090aa, moduleTitle=BMT：欧洲2022年移植和细胞治疗的规模：CAR-T稳步增长，移植增长放缓, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e8e3816090aa)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1458613, encodeId=b26f14586139a, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, objectType=article, longId=734319, objectId=1531e34319fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1531e34319fe, replyNumber=0, likeNumber=141, createdTime=2022-08-05, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1531e34319fe, moduleTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1531e34319fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458612, encodeId=87f01458612ec, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=HCT极高导致的凝血结果异常应该怎么处理？, objectType=article, longId=220903, objectId=d7ee220903b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7ee220903b1, replyNumber=0, likeNumber=105, createdTime=2021-11-25, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7ee220903b1, moduleTitle=HCT极高导致的凝血结果异常应该怎么处理？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d7ee220903b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458611, encodeId=e1ec145861176, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：auto-HCT相比CAR-T疗法更适合用作获得部分缓解的DLCLC患者的巩固治疗！, objectType=article, longId=218037, objectId=c49c21803e09, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c49c21803e09, replyNumber=0, likeNumber=81, createdTime=2021-10-03, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c49c21803e09, moduleTitle=Blood：auto-HCT相比CAR-T疗法更适合用作获得部分缓解的DLCLC患者的巩固治疗！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c49c21803e09)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458610, encodeId=c3d31458610f2, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：HCT后CD4+T细胞重建可预测急性GvHD患者的存活预后, objectType=article, longId=203527, objectId=c4e320352ed3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e320352ed3, replyNumber=0, likeNumber=89, createdTime=2020-11-20, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e320352ed3, moduleTitle=Blood：HCT后CD4+T细胞重建可预测急性GvHD患者的存活预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c4e320352ed3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458609, encodeId=fdb5145860993, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, objectType=article, longId=203318, objectId=3485203318ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3485203318ee, replyNumber=0, likeNumber=75, createdTime=2020-11-14, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3485203318ee, moduleTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3485203318ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458608, encodeId=d5ab145860843, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：GVHD预防方案中加入雷帕霉素可显著改善HLA抗原错配的HCT患者预后, objectType=article, longId=197417, objectId=d98819e41790, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d98819e41790, replyNumber=0, likeNumber=91, createdTime=2020-07-14, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d98819e41790, moduleTitle=Blood：GVHD预防方案中加入雷帕霉素可显著改善HLA抗原错配的HCT患者预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d98819e41790)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458607, encodeId=fd32145860e3f, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：预测镰状细胞病患者allo-HCT后无事件存活率的新风险评分方法, objectType=article, longId=195854, objectId=729c1958544a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=729c1958544a, replyNumber=0, likeNumber=77, createdTime=2020-06-15, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=729c1958544a, moduleTitle=Blood：预测镰状细胞病患者allo-HCT后无事件存活率的新风险评分方法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=729c1958544a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458606, encodeId=b1f01458606c4, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：纳武单抗用于alloHCT后复发的血液恶性肿瘤的疗效和安全性, objectType=article, longId=195515, objectId=098c1955156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=098c1955156f, replyNumber=0, likeNumber=79, createdTime=2020-06-10, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=098c1955156f, moduleTitle=Blood：纳武单抗用于alloHCT后复发的血液恶性肿瘤的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=098c1955156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458605, encodeId=4532145860545, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：HLA-B先导基因型预测HLA错配无血缘关系供体HCT的预后, objectType=article, longId=195463, objectId=7c2019546377, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2019546377, replyNumber=0, likeNumber=0, createdTime=2020-06-09, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2019546377, moduleTitle=Blood：HLA-B先导基因型预测HLA错配无血缘关系供体HCT的预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c2019546377)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458604, encodeId=047d145860493, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood Adv：CR1型AML患者的髓鞘异体HCT治疗后感染增加, objectType=article, longId=191597, objectId=198619159e9a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=198619159e9a, replyNumber=0, likeNumber=80, createdTime=2020-04-08, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=198619159e9a, moduleTitle=Blood Adv：CR1型AML患者的髓鞘异体HCT治疗后感染增加, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=198619159e9a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458603, encodeId=5ccb145860390, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：Brincidofovir预后异基因HCT后6B型人疱疹病毒感染的效果, objectType=article, longId=188538, objectId=3765188538a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3765188538a7, replyNumber=0, likeNumber=61, createdTime=2020-02-23, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3765188538a7, moduleTitle=Blood：Brincidofovir预后异基因HCT后6B型人疱疹病毒感染的效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3765188538a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458602, encodeId=667f14586025d, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=J Clin Oncol：alloHCT前调节化疗的强度对AML患者预后的影响, objectType=article, longId=185706, objectId=6aa8185e0619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa8185e0619, replyNumber=0, likeNumber=83, createdTime=2020-01-06, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa8185e0619, moduleTitle=J Clin Oncol：alloHCT前调节化疗的强度对AML患者预后的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6aa8185e0619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458601, encodeId=93381458601ed, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=2019 JSHCT临床实践建议：异基因造血干细胞移植后人类疱疹病毒6B脑炎的诊断和管理, objectType=article, longId=183766, objectId=cd40183e661a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd40183e661a, replyNumber=0, likeNumber=87, createdTime=2019-11-30, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd40183e661a, moduleTitle=2019 JSHCT临床实践建议：异基因造血干细胞移植后人类疱疹病毒6B脑炎的诊断和管理, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cd40183e661a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458600, encodeId=484c1458600e5, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：T细胞免疫表型的深度分析可预测HCT受体CMV再激活的风险, objectType=article, longId=157753, objectId=7c3615e753ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c3615e753ed, replyNumber=0, likeNumber=92, createdTime=2019-01-12, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c3615e753ed, moduleTitle=Blood：T细胞免疫表型的深度分析可预测HCT受体CMV再激活的风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c3615e753ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458599, encodeId=689f145859971, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：HCT-CI评分可预测非恶性血液病患者进行造血细胞移植后的死亡风险, objectType=article, longId=157423, objectId=953415e4233d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=953415e4233d, replyNumber=0, likeNumber=82, createdTime=2019-01-07, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=953415e4233d, moduleTitle=Blood：HCT-CI评分可预测非恶性血液病患者进行造血细胞移植后的死亡风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=953415e4233d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458598, encodeId=fced14585980e, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood：alloHCT前进行NGS-MRD分析，可较准确预测AML患者预后, objectType=article, longId=148500, objectId=a6fd14850017, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6fd14850017, replyNumber=0, likeNumber=73, createdTime=2018-09-10, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6fd14850017, moduleTitle=Blood：alloHCT前进行NGS-MRD分析，可较准确预测AML患者预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a6fd14850017)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458597, encodeId=4162145859ed0, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=Blood :Ibrutinib可否挽救alloHCT后复发的CLL患者？, objectType=article, longId=85769, objectId=337785e6950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=337785e6950, replyNumber=0, likeNumber=71, createdTime=2016-12-29, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=337785e6950, moduleTitle=Blood :Ibrutinib可否挽救alloHCT后复发的CLL患者？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=337785e6950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458596, encodeId=28c11458596c5, content=<a href='/topic/show?id=bc5c85640c' target=_blank style='color:#2F92EE;'>#HCT#</a>, objectTitle=ONF：对HCT住院患者睡眠质量的调查, objectType=article, longId=52813, objectId=a7635281351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7635281351, replyNumber=0, likeNumber=83, createdTime=2015-07-04, rootId=0, userName=mjldent, userId=2a376103988, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7635281351, moduleTitle=ONF：对HCT住院患者睡眠质量的调查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a7635281351)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCT

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#CAR-T# #HCT# #造血细胞移植#

BMT：欧洲2022年移植和细胞治疗的规模：CAR-T稳步增长，移植增长放缓

2024-03-07发表于上海

mjldent (审核中...)

前往app查看评论内容

#HCT#

J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益

2022-08-05

mjldent (审核中...)

前往app查看评论内容

#HCT#

HCT极高导致的凝血结果异常应该怎么处理？

2021-11-25

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：auto-HCT相比CAR-T疗法更适合用作获得部分缓解的DLCLC患者的巩固治疗！

2021-10-03

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：HCT后CD4+T细胞重建可预测急性GvHD患者的存活预后

2020-11-20

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？

2020-11-14

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：GVHD预防方案中加入雷帕霉素可显著改善HLA抗原错配的HCT患者预后

2020-07-14

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：预测镰状细胞病患者allo-HCT后无事件存活率的新风险评分方法

2020-06-15

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：纳武单抗用于alloHCT后复发的血液恶性肿瘤的疗效和安全性

2020-06-10

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：HLA-B先导基因型预测HLA错配无血缘关系供体HCT的预后

2020-06-09

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood Adv：CR1型AML患者的髓鞘异体HCT治疗后感染增加

2020-04-08

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：Brincidofovir预后异基因HCT后6B型人疱疹病毒感染的效果

2020-02-23

mjldent (审核中...)

前往app查看评论内容

#HCT#

J Clin Oncol：alloHCT前调节化疗的强度对AML患者预后的影响

2020-01-06

mjldent (审核中...)

前往app查看评论内容

#HCT#

2019 JSHCT临床实践建议：异基因造血干细胞移植后人类疱疹病毒6B脑炎的诊断和管理

2019-11-30

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：T细胞免疫表型的深度分析可预测HCT受体CMV再激活的风险

2019-01-12

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：HCT-CI评分可预测非恶性血液病患者进行造血细胞移植后的死亡风险

2019-01-07

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood：alloHCT前进行NGS-MRD分析，可较准确预测AML患者预后

2018-09-10

mjldent (审核中...)

前往app查看评论内容

#HCT#

Blood :Ibrutinib可否挽救alloHCT后复发的CLL患者？

2016-12-29

mjldent (审核中...)

前往app查看评论内容

#HCT#

ONF：对HCT住院患者睡眠质量的调查

2015-07-04

科室
- - 订阅+
  - 更多科室
工具
服务